Biorestorative Therapies, Inc. (NASDAQ:BRTX) Short Interest Update

Biorestorative Therapies, Inc. (NASDAQ:BRTX) was the recipient of a large growth in short interest in the month of May. As of May 29th, there was short interest totaling 6,588,718 shares, a growth of 1,687.2% from the May 14th total of 368,665 shares. Currently, 29.9% of the shares of the company are sold short. Based on an average trading volume of 65,163,071 shares, the days-to-cover ratio is currently 0.1 days.

Biorestorative Therapies Stock Up 9.0%

Shares of BRTX stock traded up $0.03 during trading hours on Tuesday, reaching $0.39. 1,008,341 shares of the company’s stock were exchanged, compared to its average volume of 30,628,912. Biorestorative Therapies has a fifty-two week low of $0.16 and a fifty-two week high of $2.05. The stock has a market capitalization of $10.05 million, a P/E ratio of -0.37 and a beta of 0.67. The business has a fifty day moving average price of $0.27 and a 200-day moving average price of $0.62.

Biorestorative Therapies (NASDAQ:BRTX) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.01. The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.31 million. Biorestorative Therapies had a negative net margin of 3,088.27% and a negative return on equity of 508.42%. As a group, research analysts expect that Biorestorative Therapies will post -0.66 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Citadel Advisors LLC bought a new stake in shares of Biorestorative Therapies in the third quarter valued at about $152,000. DRW Securities LLC bought a new position in Biorestorative Therapies during the fourth quarter valued at about $55,000. Finally, Virtu Financial LLC increased its stake in Biorestorative Therapies by 102.4% during the third quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock valued at $35,000 after acquiring an additional 12,319 shares during the period. Institutional investors and hedge funds own 69.38% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Biorestorative Therapies in a report on Wednesday, May 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Biorestorative Therapies presently has an average rating of “Sell”.

About Biorestorative Therapies

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.